Yderligere histologiske undersøgelser viste, at behandling med infliximab reducerer infiltreringen af inflammatoriske celler ind i den angrebne del af tarmen og tilstedeværelsen af betændelsesmarkører på disse steder.
Additional histological studies provided evidence that treatment with infliximab reduces the infiltration of inflammatory cells into affected areas of the intestine and the presence of inflammation markers at these sites.